|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
|
news & events / press releases / 2006 index / Press Release May 2006 SHIMADZU BIOTECH ENHANCES BIO-RESEARCH ANALYSES WITH NEW High-Energy MALDI CID MS/MS Instrumentation Delivers Greater Sensitivity, Flexibility COLUMBIA, Md. Shimadzu Biotech today introduced the AXIMA-TOF2, its new MALDI based high-performance TOF-TOF mass spectrometer. Representing the next generation in high-energy collision induced dissociation (CID) MS/MS instrumentation, the AXIMA-TOF2 brings enhanced flexibility to Life Science laboratories, significantly extending the type of analyses they can provide. The device was introduced today at the 54th American Society of Mass Spectrometry Conference in Seattle. With Shimadzu Biotech's intuitive software bundled as standard, the AXIMA-TOF2 is ideal for use in open-access lab environments, delivering maximum results while requiring the minimum in user input. As a result, the system is equally robust and reliable whether employed by novices, or expert users, while the inclusion of industry standard XML data exporting allows it to integrate easily and seamlessly into any workflow. Beyond its use in proteomics research, the AXIMA-TOF2 is equally adept at analyzing and processing polymers, oligonucleotides, SNPs, metabolites, lipids, carbohydrates or small molecules with extremely high sensitivity. "Using high-energy CID to augment fragmentation of analytes, Shimadzu Biotech's AXIMA-TOF2 mass spectrometer takes full advantage of the curved field reflectron technology, to deliver MS/MS data without the need for post-acceleration", says Dr. Emmanuel Raptakis, Product Manager for Shimadzu Biotech. "Ion scattering is minimized by utilizing a totally grid-less ion path and helium as the collision gas of choice. The instrument is designed to have the highest ion transmission possible, thus optimizing real-world sensitivity", "The Axima-TOF2 high energy CID has proven to be invaluable for a multitude of applications ranging from performing high confidence protein identification to aiding de novo sequencing", says Dr Rachel Martin, Applications Manager for Shimadzu Biotech. "Analysis of a wide variety of compound classes, like lipids and carbohydrates, can yield invaluable structural information previously out of reach for lower energy MS/MS approaches". The novel ion gating technology employed in the AXIMA-TOF2 affords industry-leading precursor ion isolation resolution, which allows the successful MS/MS analysis of the most challenging complex mixtures. The curved field reflectron technology, under license from Johns Hopkins University, MD, US, has been updated to enhance the sensitivity and quality of high energy CID MS/MS spectra. The Axima TOF2 is designed to seamlessly integrate with the wide Shimadzu Biotech product portfolio, to offer complete solutions. Intuitive software allows the use of this device in an open access environment with minimal training, or within the most up-to-the-minute workflows, including automated PMF or MS-MS protein identification, LC-MALDI and others. The AXIMA-TOF2 key benefits include:
-ends- About Shimadzu Biotech Shimadzu Biotech is a strategic global brand of Shimadzu Corporation. Shimadzu Biotech is focused on providing integrated solutions for life science and drug development to accelerate the progress of biotechnology in research and development. Shimadzu Biotech represents a new way of thinking in the health and life science sectors by combining a core competence in instrument design and manufacture together with strategic partnerships to advance the development of knowledge in biotechnology. Product offerings include mass spectrometry integrated with enabling technology for high throughput analysis (MALDI, LC/MS, automated systems for analyzing gels with mass spectrometry) and specific solutions for DNA analysis (ranging from UV spectroscopy to chip-based electrophoresis) among a range of other offerings. For more information, please contact:Shimadzu Biotech
Email: emmanuel.raptakis@shimadzu-biotech.net Rachel Martin, Applications Manager Tel: +44-161-888-4400, ext 304 Fax: +44-161-888-4402 Email: rachel.martin@shimadzu-biotech.net For press information, please contact: De Facto CommunicationsRichard Anderson Tel: 44-20-7496-3300 Fax: 44-20-7496-3355 Email: r.anderson@defacto.com
|
| Privacy Policy |